Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citric acid price fixing

This article was originally published in The Tan Sheet

Executive Summary

Five suppliers fined $120.5 mil. (€1=$.887) by European Commission for anti-competitive, market-sharing practices from 1991-1997, EC announces Dec. 5. Firms involved are Archer Daniels Midland, Haarmann & Reimer, Cerestar Bioproducts, Hoffmann-La Roche and Jungbunzlauer. Roche incurred largest portion, roughly $56.3 mil. Each firm was charged in proportion to its size, market share, "gravity" and "duration" of infringement, EC notes. Fines for ADM ($35.5 mil.) and Roche were increased because they acted as cartel co-leaders. Roche recently was fined more than $400 mil. by EC as one of eight firms in separate vitamin price-fixing cartel (1"The Tan Sheet" Nov. 26, In Brief)...

You may also be interested in...



Vitamin price fixing

European Commission levies $751.3 mil. fine against eight firms Nov. 21 "for participating in...distinct secret market-sharing and price-fixing cartels affecting vitamin product" from September 1989 to February 1999. Firms charged are Hoffmann-La Roche, BASF, Aventis, Merck KgaA, Solvay Pharmaceuticals, Daiichi Pharmaceutical, Eisai and Takeda Chemical Industries. Since Hoffmann-La Roche "participated in all the cartels," it received the highest fine of $405.9 mil. (1 Euro=$.878). EC decision comes roughly two years after the U.S. Department of Justice levied criminal fines of more than $850 mil. (1"The Tan Sheet" Sept. 13, 1999, p. 4)...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel